Risk Profile and 3-Year Outcomes From the SYNTAX Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting Nested Registries  by Head, Stuart J. et al.
oR
M
t
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 5 , N O . 6 , 2 0 1 2
© 2 0 1 2 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 1 9 3 6 - 8 7 9 8 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j c i n . 2 0 1 2 . 0 2 . 0 1 3Risk Profile and 3-Year Outcomes From the
SYNTAX Percutaneous Coronary Intervention and
Coronary Artery Bypass Grafting Nested Registries
Stuart J. Head, MS,* David R. Holmes, JR, MD,† Michael J. Mack, MD,‡
Patrick W. Serruys, MD, PHD,§ Friedrich W. Mohr, MD, PHD,
Marie-Claude Morice, MD,¶ Antonio Colombo, MD,# A. Pieter Kappetein, MD, PHD,*
n behalf of the SYNTAX Investigators
otterdam, the Netherlands; Rochester, Minnesota; Plano, Texas; Leipzig, Germany;
assy, France; and Milan, Italy
Objectives The aim of this study was to evaluate the use of percutaneous coronary intervention
(PCI) and coronary artery bypass grafting (CABG) in “real-world” patients unsuitable for the alterna-
tive treatment.
Background No data are available on the risk proﬁle and outcomes of patients that can only un-
dergo PCI or CABG.
Methods In the SYNTAX (Synergy between PCI with TAXUS and Cardiac Surgery) trial, a multidisci-
plinary Heart Team reached a consensus on whether PCI and CABG could result in clinical equipoise;
if so, the patient was randomized. If not, the patient was enrolled in a CABG-ineligible PCI registry
or PCI-ineligible CABG registry. A proportion (60%) of patients in the CABG registry was randomly
assigned to be followed up for 5 years. No statistical comparisons were performed between ran-
domized and registry patients. Major adverse cardiac or cerebrovascular event (MACCE) rates are
presented as observational only.
Results A total of 3,075 patients were treated in the SYNTAX trial; 198 (6.4%) and 1,077 (35.0%)
patients were included in PCI and CABG registries, respectively. The main reason for inclusion in the
CABG registry was too complex coronary anatomy (70.9%), and the main reason for inclusion in the
PCI registry was too high-risk for surgery (70.7%). Three-year MACCE was 38.0% after PCI and 16.4%
after CABG. Stratiﬁcation by SYNTAX score terciles demonstrated a step-wise increase of MACCE
rates in both PCI and CABG registries.
Conclusions The SYNTAX Heart Team concluded that PCI and CABG remained the only treatment
options for 6.4% and 35.0% of patients, respectively. Inoperable patients with major comorbidities
that underwent PCI had high MACCE rates. In patients not suitable for PCI, surgical results were ex-
cellent. (SYNTAX Study: TAXUS Drug-Eluting Stent Versus Coronary Artery Bypass Surgery for the
Treatment of Narrowed Arteries, NCT00114972) (J Am Coll Cardiol Intv 2012;5:618–25) © 2012 by
he American College of Cardiology Foundation
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619Since the 1980s, coronary artery bypass graft surgery
(CABG) is the treatment of choice for patients with
multivessel and/or left main (LM) coronary artery disease.
Numerous trials have compared CABG with percutaneous
coronary intervention (PCI) but have not been able to
produce favorable outcomes after PCI due to an excess in
repeat revascularization (1).
The recent SYNTAX (Synergy between PCI with
TAXUS and Cardiac Surgery) trial showed that CABG
remains superior to PCI, even with the usage of drug-
eluting stents (DES) (2). It has been demonstrated that PCI
is as effective as CABG in subgroups of patients with less
complex coronary artery disease and LM lesions (2–4).
Other recent trials have confirmed more favorable outcomes
with CABG (5,6).
Although CABG is still the gold standard, there are some
patients who cannot undergo surgery. In addition, a pro-
portion of patients are not eligible for PCI. The SYNTAX
study was designed as an all-comers trial, but patients could
be excluded if the Heart Team concluded that either PCI or
CABG could not be performed (2,7). This decision was
based on a team judgment and not on predefined criteria.
Excluded patients were entered in a CABG registry to
define the population at too high-risk for PCI and in a PCI
registry to define the patients deemed unsuitable for surgery.
Little is known of the characteristics and outcomes of these
populations. Separate analysis is necessary to fully under-
stand the strengths and limitations of PCI and CABG in
the “real world” (8). This study presents characteristics and
3-year outcomes of patients that were deemed nonrandom-
izable and therefore were included in the SYNTAX PCI
and CABG nested registries.
Figure 1. SYNTAX Patient Distribution
CABG  coronary artery bypass grafting; PCI  percutaneous coronary
intervention; SYNTAX  Synergy Between PCI With TAXUS and Cardiaca
Surgery.Methods
Study design. The SYNTAX trial design has been de-
scribed previously (2,9). In brief, patients with 3-vessel or
LM coronary artery disease were screened for enrollment in
the randomized trial. During a multidisciplinary Heart
Team discussion, including at least 1 surgeon and 1 inter-
ventional cardiologist, consensus was reached on whether
both PCI and CABG would result in clinical equipoise (7).
If a patient was not eligible for randomization, the patient
was enrolled in the nested registry for CABG-ineligible
patients (PCI registry) or PCI-ineligible patients (CABG
registry).
Patients in the PCI registry were treated according to
local practices with regard to technique and device prefer-
ence, either with or without DES.
To compare the risk profile and outcomes of patients in
the registries with the randomized arms, a randomly se-
lected proportion of patients from the CABG registry and
all PCI registry patients were
scheduled to undergo clinical
follow-up at 1, 6, 12, 36, and 60
months after treatment alloca-
tion (9).
The study protocol was approved
by the institutional review board of
all 85 enrollment sites and is consis-
tent with the International Confer-
ence on Harmonisation Guidance
of Industry E6 Good Clinical Prac-
tice, the Declaration of Helsinki,
and all local regulations. Written
consent was obtained from all par-
ticipating patients. SYNTAX is
registered at ClinicalTrials.gov
(NCT00114972).
Deﬁnitions. The primary outcome of this study was the
omposite of major adverse cardiac or cerebrovascular events
MACCE) at 3 years of follow-up. MACCE included
ll-cause death, stroke, myocardial infarction (MI), and any
epeat revascularization. The composite safety endpoint
onsisting of all-cause death, stroke, and MI, was also
nalyzed as well as individual outcomes. Adverse events
ere adjudicated by an independent Clinical Events
ommittee.
Definitions have been reported elsewhere (4). Briefly,
troke was defined as a focal neurological deficit of central
rigin lasting 72 h resulting in permanent brain damage
r body impairment. Myocardial infarction was defined in
elation to intervention status as follows: 1) after allocation
ut before treatment: Q-wave MI (new pathological Q
aves in 2 leads lasting 0.04 s with creatine kinase-
yocardial band [CK-MB] levels elevated above normal)
Abbreviations
and Acronyms
CABG  coronary artery
bypass grafting
DES  drug-eluting stent(s)
LM  left main
MACCE  major adverse
cardiac or cerebrovascular
event(s)
MI  myocardial infarction
PCI  percutaneous
coronary intervention
SYNTAX  Synergy Between
PCI With TAXUS and Cardiac
Surgerynd non–Q-wave MI [elevation of CK levels 2 the
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620upper limit of normal [ULN] with positive CK-MB or
elevation of CK levels to 2  ULN without new Q waves
f no baseline CK-MB was available); 2) 7 days after
ntervention: new Q waves and either peak CK-MB/total
Table 1. Baseline Patient Demographic Data and Les
Characteristics
P
(n 
Age, yrs 71.2
Male 70.3% (
Comorbid risk factors
Body mass index (kg/m2) 28.0
Medically treated diabetes
Any 35.4% (
Requiring insulin 15.1% (
Triglycerides 150 mg/dl (1.7 mmol/l) 33.6% (
Blood pressure 130/85 mm Hg 69.8% (
Fasting glucose 110 mg/dl 47.2% (
Increased waist circumference 40.8% (
Hyperlipidemia 67.5% (
Cardiovascular history
Current smoker 11.2% (
Previous myocardial infarction 40.4% (
Previous stroke 7.8% (
Previous transient ischemic attack 7.9% (
Previous cardiac surgery 1.6% (
Congestive heart failure 9.7% (
Peripheral vascular disease 16.1% (
Carotid artery disease 10.4% (
Creatinine 200 mol/l 5.7% (
Chronic obstructive pulmonary disease 19.3% (
Angina
Stable 46.4% (
Unstable 38.0% (
Ejection fraction 30% 5.7% (
Logistic EuroSCORE 7.7
Additive EuroSCORE 5.8
Parsonnet score 14.4
Lesion complexity
SYNTAX score 31.6
Diffuse disease or small vessels 18.5% (
Total occlusion 36.5% (
Bifurcation 74.6% (
Lesion characteristics
Number of lesions 4.5
Left main, any 33.3% (
Left main only 2.6% (
Left main  1 vessel 5.8% (
Left main  2 vessel 11.6% (
Left main  3 vessel 13.2% (
3-vessel disease only 66.7% (
Values are mean SD (N) or % (n/N).
CABG  coronary artery bypass grafting; na  not available; PCI TAXUS and Cardiac Surgery.K10% or plasma level of CK-MB 5 ULN; and 3)7
ays after intervention: new Q waves or peak CK-MB/total
K 10% or plasma level of CK-MB 5  ULN or plasma
evel of CK 5  ULN (4).
haracteristics
CABG
With Follow-Up
(n  644)
All
(n  1,072)
92) 65.7 9.4 (644) 65.9 9.4 (1,072)
2) 80.7% (520/644) 81.1% (869/1,072)
) 28.0 4.6 (643) 28.0 4.6 (1,069)
) 29.7% (191/644) 30.3% (325/1,072)
) 9.2% (59/644) 9.2% (99/1,072)
) 39.6% (114/288) 40.4% (182/451)
2) 68.5% (441/644) 68.9% (735/1,067)
) 49.8% (210/422) 49.7% (338/680)
) 46.4% (245/528) 48.1% (414/861)
1) 76.4% (480/628) 77.1% (809/1,049)
) 21.9% (140/639) 19.7% (209/1,062)
) 33.5% (211/629) 32.5% (341/1,049)
) 5.5% (35/639) 4.5% (48/1,065)
) 5.6% (36/638) 6.0% (64/1,062)
0.0% (0/644) 0.0% (0/1,072)
) 5.5% (35/633) 5.1% (54/1,057)
) 13.8% (89/644) 12.5% (134/1,072)
) 12.3% (79/644) 10.2% (109/1,072)
) 2.0% (13/644) 2.1% (23/1,072)
) 7.9% (51/644) 7.3% (78/1,072)
) 62.9% (405/644) 63.3% (678/1,071)
) 21.6% (139/644) 22.5% (241/1,071)
) 4.5% (29/644) 3.9% (42/1,072)
) 4.0 4.4 (644) 4.0 4.8 (1,072)
) 3.9 2.7 (644) 3.9 2.7 (1,072)
) 9.0 7.1 (644) 9.1 7.2 (1,072)
9) 37.8 13.3 (632) na
) 13.6% (86/631) na
) 56.4% (356/631) na
9) 80.8% (510/631) na
) 4.6 1.7 (632) na
) 40.3% (254/631) na
1.6% (10/631) na
) 2.7% (17/631) na
) 8.4% (53/631) na
) 27.6% (174/631) na
9) 59.7% (377/631) na
aneous coronary intervention; SYNTAX  Synergy between PCI withion C
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621Statistical analysis. Analyses were performed with SAS
system software, version 8.0 or higher (SAS Institute, Cary,
North Carolina). Outcomes are presented according to the
as-treated-principle. The composite MACCE endpoint was
analyzed as the time to the first event, whereas individual
MACCE components are presented as proportions. Patient
characteristics are presented as proportions (%, count/
sample size) or mean  SD.
We decided that no statistical comparisons between PCI
and CABG should be performed, because entry into the
registries depended on different variables specific for the
corresponding registry. Thus, the patient characteristics and
outcomes are only representative of patients ineligible to
undergo PCI or CABG. Results are presented as observa-
tional only.
Subgroup analyses of separate SYNTAX score cohorts
(low 0 to 22, intermediate 23 to 32, and high 33) were
performed (10). The assessment of coronary anatomic
complexity by SYNTAX score was based on tercile
cohorts established in the randomized trial (2). Statistical
comparison was performed by overall and pairwise log-rank
testing, with a 2-sided p value 0.05 considered statistically
ignificant.
esults
Inclusion. Between March 2005 and April 2007, a total of
4,337 patients were screened for eligibility of enrollment in
the trial. After exclusion due to variable reasons (e.g., refusal
of informed consent or concomitant valvular heart disease,
among others), a total of 3,075 patients were treated within
the SYNTAX trial. In the trial 1,800 patients were ran-
domly assigned to undergo PCI (n 903) and CABG (n
897). Another 198 (6.4%) and 1,077 (35.0%) patients were
included in the PCI and CABG registries, respectively
(Fig. 1). From the 1,077 in the CABG registry, 649 were
randomly selected to be followed-up for 5 years.
Of the 198 patients in the PCI registry, 192 were treated
with PCI, 4 patients were treated medically, 1 underwent
CABG, and 1 patient withdrew consent. Of the 649 CABG
registry patients randomly assigned to 5-year follow-up, 644
were treated with CABG, 3 did not receive treatment, and
2 were managed medically. Another 9 patients were lost to
follow-up, and 3 patients withdrew consent. Three-year
MACCE rates were evaluable in 100% and 97.2% of the
PCI and CABG patients, respectively.
Patients included in the PCI registry were considered too
high-risk for CABG (70.7%), had no graft material for
anastomosis (9.1%), refused CABG (5.6%), had small or
poor quality of distal vessels (1.5%), or were excluded from
randomization because of other reasons (13.1%). Reasons
for inclusion in the CABG registry included too complex
coronary anatomy to undergo PCI (70.9%), chronic total
occlusion untreatable with PCI (22.0%), unable to takeantiplatelet medication (0.9%), refusal to undergo PCI
(0.5%), or other reasons (5.7%).
Patient characteristics. In general, compared with the pa-
ients that were randomized in the SYNTAX trial, the
atients in the PCI registry were older (71.2 10.4 years vs.
5.2  9.7 years) and had a high-risk profile because of
omorbidities and an eventful cardiovascular and noncar-
iovascular history; this was manifested in a higher Logistic
uroSCORE of 7.7 9.0 (vs. 3.8 4.5 in the randomized
CI group) and Parsonnet score of 14.4 9.5 (vs. 8.5 7.0
n the randomized PCI group) (Table 1). In addition, the
esion complexity by SYNTAX score was 31.6 12.3 in the PCI
egistry, which was slightly higher than the 28.4 11.5 in the
andomized PCI group. A total occlusion was present in
6.5%, whereas this rate was only 24.2% in the trial.
Table 2. Perioperative Medication Use
PCI (n  192) CABG (n  644)
Aspirin
Baseline 83.3% (160/192) 74.7% (481/644)
Discharge 92.7% (178/192) 88.4% (569/644)
Thienopyridine
Baseline 71.9% (138/192) 16.1% (104/644)
Discharge 92.7% (178/192) 16.9% (109/644)
Nonthienopyridine antiplatelet
Baseline 9.9% (19/192) 8.7% (56/644)
Discharge 6.8% (13/192) 6.1% (39/644)
Warfarin derivative
Baseline 4.7% (9/192) 3.9% (25/644)
Discharge 3.6% (7/192) 9.6% (62/644)
Statin
Baseline 64.1% (123/192) 70.0% (451/644)
Discharge 71.9% (138/192) 68.3% (440/644)
Beta-blocker
Baseline 67.7% (130/192) 77.3% (498/644)
Discharge 70.3% (135/192) 79.3% (511/644)
ACE inhibitor
Baseline 43.8% (84/192) 47.2% (304/644)
Discharge 54.2% (104/192) 45.2% (291/644)
Calcium-channel blocker
Baseline 30.2% (58/192) 27.8% (179/644)
Discharge 27.1% (52/192) 21.9% (141/644)
Angiotensin II-receptor
antagonist
Baseline 16.1% (31/192) 11.3% (73/644)
Discharge 12.5% (24/192) 5.3% (34/644)
Antiarrythmic (amiodarone)
Baseline 1.6% (3/192) 2.5% (16/644)
Discharge 2.6% (5/192) 12.3% (79/644)
H2-receptor blocker
Baseline 4.7% (9/192) 8.9% (57/644)
Discharge 8.9% (17/192) 19.9% (128/644)
Values are % (n/N).ACE angiotensin-converting enzyme; other abbreviations as in Table 1.
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622Patients in the CABG registry had a Logistic Euro-
SCORE comparable to the CABG patients in the random-
ized trial (4.0  4.4 vs. 3.9  4.4 in the randomized trial)
s well as a similar mean Parsonnet score (9.0  7.1 vs.
.4  6.8 in the randomized CABG group) (Table 1).
owever, the lesions were more complex in the registry:
he SYNTAX score was 37.8  13.3 in the registry versus
9.1  11.4 in the randomized trial. A total occlusion
as present in 56.4% versus 22.2% in the randomized
rial. More patients had LM and 3-vessel disease in the
egistry (27.6% vs. 13.0% in the trial).
Procedural characteristics. In the PCI registry, a mean of
2.5  1.3 lesions were treated with 3.1  1.8 stents and a
mean total length of 58.5  41.2 mm. This is much lower
than in the randomized trial where 3.6  1.6 lesions were
treated with 4.6  2.3 stents and a mean length of 86.1 
7.9 mm. In 76% of cases a DES stent (57% TAXUS) was
sed. Completeness or revascularization was only 36.5% in
he registry compared with 56.7% in the trial.
A total of 3.0  0.9 conduits were used per CABG
atient (vs. 2.8  0.7 in the randomized trial), of which
.3  0.7 were arterial and 1.7  1.0 venous grafts.
Complete arterial revascularization was performed in 11.2%
compared with 18.9% in the randomized trial. In 96.7% at
least 1 arterial graft was used; in the randomized trial this
rate was 97.3%. Off-pump surgery was performed slightly
more often in the registry (18.6% vs. 15.0% in the trial).
Completeness of revascularization was 74.7% in the registry,
compared with 63.2% in the trial.
Mean post-procedure hospital stay was 8.2  5.5 days
nd 4.8  12.0 days in the CABG and PCI registries,
espectively. Perioperative medication use is displayed in
able 2.
PCI outcomes. Procedural 30-day MACCE occurred in
7.6% of the patients (Table 3). This was mainly driven by
the 3.1% death rate and 3.6% MI rate. After 3 years of
Table 3. Outcomes of Patients in PCI and CABG Registries
PCI (n  192)
30 Days
(n  192)
6 Months
(n  191)
1 Yr
(n  191)
Composite MACCE 7.3% (14) 14.1% (27) 20.4% (39)
Composite death/stroke/MI 6.3% (12) 8.4% (16) 10.5% (20)
Death 3.1% (6) 5.2% (10) 7.3% (14)
Cardiac death 2.6% (5) 3.7% (7) 4.7% (9)
Stroke 0.0% (0) 0.0% (0) 0.0% (0)
MI 3.6% (7) 3.7% (7) 4.2% (8)
Repeat revascularization, any 1.6% (3) 7.3% (14) 12.0% (23)
PCI 1.0% (2) 6.8% (13) 11.0% (21)
CABG 0.5% (1) 0.5% (1) 1.0% (2)
Values are % (n).
MACCEmajor adverse cardiac and cardiovascular event(s); MImyocardial infarction; other afollow-up, the MACCE rate was 38.0% (Fig. 2, Table 3), with18.3% death, 8.4% MI, 1.8% stroke, and 20.0% repeat revas-
cularization (repeat PCI 17.8%, and repeat CABG 2.8%).
According to the SYNTAX score terciles, 44 patients had
low lesion complexity (mean SYNTAX score 16.5  5.1),
63 patients had intermediate complexity (mean SYNTAX
score 27.7  2.8), and 82 patients had high complexity
(mean SYNTAX score 42.4  9.2). Subgroup analyses
revealed a MACCE rate of 29.5% in the cohort with a score
22 and increasing rates with intermediate (33.3%) and
high (46.3%) scores (overall p  0.09) (Fig. 3A). Difference
in MACCE was not statistically significant between the
low- and intermediate-score groups (p  0.64) and
intermediate- and high-score groups (p  0.11). There was
a trend toward a difference between the low- and high-score
groups (p  0.06). Breaking down MACCE into separate
endpoints (Fig. 4A), there was a significant difference
between the groups in terms of the composite safety
endpoint of death, stroke, and MI (13.9% vs. 32.9% and
20.6% vs. 32.9%, p  0.04), which was driven by increased
rates of death in the high SYNTAX score group (24.4% vs.
9.3% in the low SYNTAX score group, p  0.04). Other
endpoints were comparable between groups (Fig. 4A).
CABG (n  644)
3 Yrs
(n  192)
30 Days
(n  641)
6 Months
(n  639)
1 Yr
(n  633)
3 Yrs
(n  626)
38.0% (73) 3.4% (22) 6.7% (43) 8.8% (56) 16.4% (104)
24.6% (47) 3.3% (21) 5.8% (37) 6.6% (42) 12.6% (80)
18.3% (35) 0.6% (4) 2.2% (14) 2.5% (16) 6.9% (44)
7.0% (13) 0.5% (3) 1.4% (9) 1.4% (9) 2.5% (16)
1.8% (3) 1.2% (8) 2.0% (13) 2.2% (14) 3.8% (24)
8.4% (15) 1.6% (10) 2.2% (14) 2.5% (16) 3.7% (23)
20.0% (36) 0.3% (2) 1.4% (9) 3.0% (19) 5.7% (35)
17.8% (32) 0.2% (1) 1.3% (8) 2.8% (18) 5.5% (34)
2.8% (5) 0.2% (1) 0.2% (1) 0.2% (1) 0.2% (1)
tions as in Table 1.
Figure 2. Cumulative Incidence of MACCE After PCI or CABG
CABG  coronary artery bypass grafting; MACCE  major adverse cardiac
or cerebrovascular event(s); PCI  percutaneous coronary intervention.
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623CABG outcomes. Procedural outcomes after CABG showed
low rates of MACCE (3.4%), for the composite safety
endpoint of death/stroke/MI (3.3%), and the individual
components of MACCE: stroke (1.2%), MI (1.6%), and
repeat revascularization (0.3%) (Table 2). After 3 years, the
MACCE rate was 16.4% (Fig. 2, Table 3).
Patients were divided into low lesion complexity (n 68,
SYNTAX score 16.8  4.1), intermediate complexity (n 
161, SYNTAX score 28.2 2.7), and high complexity (n
403, SYNTAX score 45.2  10.1). Subgroup analysis
demonstrates a stepwise increase in MACCE with higher
SYNTAX score; 9.0% in the low-, 13.8% in the
intermediate-, and 18.3% in the high-score cohorts (overall
p  0.10) (Fig. 3B). Pairwise testing demonstrated no
statistically significant differences (low vs. intermediate, p
0.32; intermediate vs. high, p  0.19; low vs. high, p 
0.07). Individual MACCE components were not statisti-
cally significant between groups, except for the endpoint of
death where there was a difference between the intermediate
and high score groups (p  0.03) (Fig. 4B).
Discussion
The SYNTAX nested registries presented in this study are
important to complete the knowledge of the current use of
PCI and CABG for 3-vessel or LM coronary artery disease
in the real world. The SYNTAX randomized trial, among
other trials, included only selective patients in whom both
PCI and CABG could be performed with satisfactory
Figure 3. MACCE After PCI or CABG Stratified by SYNTAX Score
Kaplan-Meier incidence of MACCE in the PCI registry (A) and CABG registry (B).
Abbreviations as in Figures 1 and 2.results. Those patients not suitable for randomization are acrucial to fully understand the indications, strengths, and
limitations of PCI and CABG, with the corresponding
outcomes. In this study we showed that the Heart Team
decided that 35.0% of patients were not suitable for PCI
and therefore underwent CABG. Patients were deemed
inoperable and received PCI treatment in 6.4% of the cases.
Other studies. Patients in these registries were selected on
he basis of clinical judgment of a multidisciplinary team of
hysicians (7). Results from other studies cannot be compared
ith the SYNTAX registry results, because this study presents
atients in whom only 1 treatment option was considered
ppropriate. Therefore these patients represent not the total
CI or CABG cohort but only a selected group with different
aseline risk and lesion complexity. Many patients receiving
ither PCI or CABG in other studies would probably have
een randomized in the SYNTAX trial (2).
PCI registry. Patients in the SYNTAX PCI registry present
a completely different patient population as the patients
described in other registries or trials (1,2,11–13). First, the
mean age was 71.2  10.4, and nearly 75% of patients were
65 years of age; thus patients were significantly older.
econd, patients more often presented with an eventful
ardiac and noncardiac history. The mean Logistic Euro-
CORE was higher in the registry (7.7  9.0) than in the
andomized arm (3.8  4.5) as well as the Parsonnet score
14.4  9.5 compared with 8.5  7.0, respectively).
Indeed, the 3-year 38.0% MACCE rate in the PCI
egistry was much higher than the 28.0% in the randomized
rial. However, this is not unexpected, due to the advanced
ge and severe comorbidities. Both the EuroSCORE and
arsonnet score have been associated with increased rates of
dverse events during follow-up (13–15). In addition, some
f the patients were included in the PCI registry because
hey had cancer or other severe diseases. This could be one
f the reasons that the death rate is very high.
The high-risk profile of these PCI patients was influential
n choosing the treatment strategy. Fewer lesions were
tented and the number of stents that were used was much
ower. It might be the case that only the culprit lesion was
tented, whereas other lesions remained untreated, resulting
n a 63.5% rate of incomplete revascularization in the
egistry. Also, 24% of patients received a bare-metal stent;
his might have had an influence on the results as well (16).
CABG registry. Patients included in the CABG registry
represent a population completely different from the pa-
tients in the PCI registry. Where in the PCI registry
patients were high-risk but had similar lesion complexity, in
the CABG registry it was the exact opposite. Patients had a
similar mean EuroSCORE (4.0  4.4 vs. 3.9  4.4) and
Parsonnet score (9.0 7.1 vs. 8.4 6.8) as the randomized
atients. However, they were most often denied PCI
ecause of too complex coronary anatomy, demonstrated in
higher SYNTAX score (37.8  13.3 vs. 29.1  11.4),
t
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624more patients with a total occlusion (56.4% vs. 22.2%), and
a slightly higher rate of bifurcation (80.8% vs. 73.3%).
The 3-year MACCE rate in the CABG registry (16.4%)
is actually lower than in the randomized patients (20.2%),
which was caused by lower rates of repeat revascularization
(4,17). Interestingly, however, the actual difference in
MACCE rates between the registry and trial do not increase
over follow-up. At 1 year the difference was 3.2%, and at 3
years this was still only 3.8%. Therefore, it seems that the
registry patients did significantly better especially during short-
term follow-up. This was confirmed by a trend in lower rates
of hospital and 30-day MACCE rates in the registry patients
(17). This lower incidence of MACCE cannot be described by
a difference in risk profile, because patients had similar risk. A
Figure 4. Outcomes Within the PCI and CABG Registries Stratified by SYN
Event rates in the PCI registry (A) and CABG registry (B). *p  0.05 for low
sus high SYNTAX score group comparison. composite  composite of deat
as in Figures 1 and 2.previous study showed that it was likely related to procedural Rcharacteristics (17). In the registry, patients had a 74.7% rate of
complete revascularization, whereas this was only 63.2% in the
randomized trial. Furthermore, the number of grafts and distal
anastomoses per patient was higher, which was identified to be
independently associated with reduced rates of MACCE (17).
SYNTAX score. Since 2009, a large number of studies have
ested the accuracy of the SYNTAX score as a risk algo-
ithm in predicting adverse outcomes. A recent review
ummarized these data and concluded that, especially in
M patients treated with PCI, the score is a useful
rognostic tool (18). Although Birim et al. (19) reported a
tepwise increase in MACCE rates with higher SYNTAX
cores, in patients treated with CABG generally less discrim-
native power could be attributed to the SYNTAX score.
core
s high SYNTAX score group comparison. †p  0.05 for intermediate ver-
ke/myocardial infarction; MI  myocardial infarction; other abbreviationsTAX S
versu
h/stroemarkably, this study shows that in both PCI and CABG
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625patients a stepwise increase of MACCE rates can be seen with
higher SYNTAX scores, although this was not statistically
significant in the CABG registry.
There was, however, a significant difference in death
between the intermediate- and high-score groups. A hy-
pothesis behind this finding is that in the high SYNTAX
score group more patients with extreme high scores were
present. Although the predictive power of the SYNTAX
score is limited in CABG patients, with extreme scores it is
likely that ultimately the score will identify those patients at
higher risk. The fact that death did not increase stepwise from
low- to high-score groups demonstrates that the increased
death in cohort with scores 33 might be caused by these
extreme cases. Furthermore, these intragroup comparisons are
post hoc subgroup analyses with relatively low statistical power,
thus a change finding cannot be ruled out.
Study limitations. It is important to recognize that an empha-
sis should lay on long-term results after PCI and CABG.
From this study, follow-up is only available up to 3 years.
Ongoing prospective data collection will provide 5-year results.
The PCI registry contains a relatively small number of patients.
Therefore some of the results should be interpreted with caution.
Furthermore, explorative subgroup analyses by lesion subsets could
not performed, due to the low patient number in separate groups.
Conclusions
In the SYNTAX trial the Heart Team concluded that, for
6.4% and 35.0% of patients, the only treatment option was
PCI or CABG, respectively. Patients with complex coro-
nary anatomy often underwent CABG, whereas inoperable
high-risk patients were included in the PCI registry. Pa-
tients deemed inoperable for CABG had a high-risk profile,
resulting in a suboptimal outcome after PCI. In patients
who are not candidates for PCI, bypass surgery produces
excellent results. To identify those patients at high risk for
MACCE, the SYNTAX score discriminates well.
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